TransMedics Group, Inc. (NASDAQ: TMDX) saw its stock price surge 9.33% in after-hours trading on Thursday, following the release of its exceptional first-quarter 2025 financial results that significantly outperformed analyst expectations.
The medical technology company reported quarterly earnings of $0.70 per share, surpassing the analyst consensus estimate of $0.25 by an impressive 180%. This represents a 100% increase from the $0.35 per share reported in the same period last year. TransMedics' quarterly sales reached $143.54 million, beating the analyst consensus estimate of $123.66 million by 16.07% and marking a 48.21% increase from the $96.85 million reported in the previous year.
Other highlights from the Q1 report include income from operations of $27.443 million, far exceeding the IBES estimate of $10.1 million. The company also achieved a robust gross margin of 61% and reported a net income of $25.682 million. Looking ahead, TransMedics provided a strong full-year revenue outlook of $565-585 million, further bolstering investor confidence. The company's outstanding performance across multiple financial metrics likely contributed to the significant after-hours stock price increase.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.